Martin Bonde, CEO Vaccibody.

Dynamic networking and pitch sessions at ICCS 2019

Oslo Cancer Cluster and its international partners organised the International Cancer Cluster Showcase (ICCS) on 3 June in Philadelphia, kickstarting this year’s BIO International Convention.

International Cancer Cluster Showcase 2019

The aim of this annual event is to showcase cutting edge oncology research and development activities performed in start-ups and biotechs from Oslo Cancer Cluster and its international partners from North America and Europe.

This year’s meeting offered a compact program including company presentations, engaging poster sessions and lively networking among representatives of the international oncology community.

Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, and main organizer of the event:

“Building on the first meeting at the Whitehead Institute in Cambridge in 2012, ICCS was established as a successful format to expose and connect emerging oncology companies to executives of the global oncology community attending the BIO International Convention.

“Via collaboration with partners from North American and European innovation hubs, we gather a strong group of exciting new companies and attract more than 200 participants.”

Jan Alfheim, CEO of Oncoinvent, another member of Oslo Cancer Cluster also held a presentation.

Jan Alfheim, CEO of Oncoinvent, another member of Oslo Cancer Cluster also held a presentation.

Among this year’s presenters were our members OncoInvent and Vaccibody. The dynamic pitch session featured 20 companies from 9 countries advancing a variety of innovative oncology technologies and assets in preclinical and clinical development.

“ICCS was a great opportunity to present Vaccibody and our recent progress towards a relevant international audience. It triggered new contacts and stimulated good discussions following the presentation.”
Martin Bonde, CEO of Vaccibody

Commenting on the highlights, Heix said:

“The National Institutes of Health / National Cancer Institute (NCI) participated for the 2nd time. Michael Salgaller, Supervisory Specialist Technology Transfer Center presented the partnering opportunities and benefits the NCI offers to outside parties from academia and industry.

“Our sponsors Precision for Medicine, Takeda Oncology and Boehringer Ingelheim enriched the program by short presentations and active discussions during the humming poster and networking sessions.”

 

The event was sponsored by:

Boehringer Ingelheim logoDNB logoeaec logo

Precision for medicine logo Takeda logo

 

The event was organised by:

Logos of the event organisers

Ultimovacs enter Oslo Stock Exchange

Ultimovacs enters the Oslo Stock Exchange

Oslo Cancer Cluster member Ultimovacs, a Norwegian cancer vaccine company, has raised NOK 370 million and entered the Oslo Stock Exchange on Monday 3 June 2019.

There was a stir of interest among both national and international investors when Ultimovacs announced they will enter the Oslo Stock Exchange. Several interested parties have now become shareholders in the company, totalling approximately 1 500 shareholders.

“It is good for the Norwegian health industry and for Ultimovacs when national and international investors show the company this kind of trust. In today’s uncertain market, it is especially nice with such a large interest, from both international investors and small savers. I look forward to following the company further,” says Jonas Einarsson, Chairman of the Board in Ultimovacs and Managing Director in Radforsk.

The funds that Ultimovacs has raised will go to financing the development of their universal cancer vaccine, UV1. A large clinical study will document the effect of the vaccine. UV1 will be combined with other immunotherapies in patients with malignant melanoma (a type of skin cancer) at around 30 hospitals in Norway, Europe, USA and Australia.

Ultimovacs has already run two successful clinical trials of the vaccine on patients with lung cancer, prostate cancer and malignant melanoma.

“The cancer vaccine has shown promise in the studies we have conducted at the Norwegian Radium Hospital. Based on the results, we have established a development programme to document that our vaccine has effect on cancer patients. I am very happy that we now have entered the Oslo Stock Exchange. It means that the practical conditions are in place to put our development programme into action,” said Øyvind Kongstun Arnesen, Chief Executive Officer in Ultimovacs.

Sign up to OCC newsletter

Emmy and Benedicte learned about research into neuroscience and how to use modern medical technology, such as CRISPR, when on work placement with researcher Marianne Fyhn and her colleagues at the University of Oslo. Photo: Monica Jenstad

Learning about the human brain

Oslo Cancer Cluster and Ullern Upper Secondary School arranged a work placement for students to learn about neuroscience at the University of Oslo.

Four biology students from Ullern Upper Secondary School spent two great days on work placement with some of the world’s best neuroscientists at the University of Oslo. In Marianne Fyhn’s research group, the students tried training rats and learned how research on rats can provide valuable knowledge about the human brain.

The Ullern students, Benedicte Berggrav, Lina Babusiaux, Maren Gjerstad Høgden and Emmy Hansteen, first had to dress in green laboratory clothes, hairnets and gloves. They also had to leave their phones and notepads behind, before enterring the animal laboratory where Marianne Fyhn and her colleagues work. Finally, they had to walk through an air lock that blew the last remnants of dust and pollution off them.

On the other side was the most sacred place for researchers: the newly refurbished animal laboratory. It is in the basement of Kristine Bonnevies Hus on the University of Oslo campus. We used to call it “Bio-bygget” (“the bio-building”) when I studied here during the ‘1990s.

 

Researcher Kristian Lensjø showed the four excited biology students into the most sacred place: the animal lab.

Researcher Kristian Lensjø showed the four excited biology students into the most sacred place: the animal lab.

It is the second day of the students’ work placement with Marianne. The four biology students, who normally attend the second year of Ullern Upper Secondary School, have started to get used to their new, temporary jobs. They are standing in one of the laboratories and looking at master student Dejana Mitrovic as she is operating thin electrodes onto the brain of a sedated rat. PhD student Malin Benum Røe is standing behind Dejana, watching intently, giving guidance and a helping hand if needed.

“We do this so we can study the brain cells. We will also find out if we can guide the brain cells with weak electrical impulses. This is basic scientific research. In the long term, the knowledge can help to improve how a person with an amputated arm can control an artificial prosthetic arm,” Marianne explained.

“The knowledge can help to improve how a person with an amputated arm can control an artificial prosthetic arm.”

Dejana needs to be extremely precise when she connects the electrodes onto the rat’s brain. This is precision work and every micrometre makes a difference.

 

Training rats

The previous day, Maren, Benedicte, Lina and Emmy helped to train the rat on the operating table on a running course. Today, the Ullern students will train the other rats that haven’t had electrodes surgically connected to their brains yet.

“We will train the rats to walk in figures of eight, first in one direction and then the other”, the students explained to me.

We remain standing in the rat training room for a while, talk with Dejana and train some of the rats. Dejana tells me that the rats don’t have any names. After all, they are not pets, but they are cared for and looked after in all ways imaginable.

“It is very important that they are happy and don’t get stressed. Otherwise, they won’t perform the tasks we train them to do,” says Dejana. She and the other researchers know the animals well and know to look for any signs that may indicate that the rats aren’t feeling well.

“It is very important that they are happy and don’t get stressed.”

I ask the students how they feel about using rats for science.

“I think it is completely all right. The rats are doing well and can give us important information about the human brain. It is not okay when rats are used to test make-up and cosmetics, but it is a whole different matter when it concerns important medical research,” says Emmy and the other biology students from Ullern nod in agreement.

 

Understanding the brain

Marianne is the head of the CINPLA centre at the University of Oslo, where Maren, Benedicte, Lina and Emmy are on work placement for two days. Four other Ullern students, Henrik Andreas Elde, Nils William Ormestad Lie, Hans Christian Thagaard and Thale Gartland, are at the same time on a work placement with Mariannes research colleague, Professor of Physics Anders Malthe-Sørenssen. They are learning about methods in physics, mathematics and programming that help researchers to better understand the brain.

“CINPLA is an acronym for Centre for Integrative Neuroplasticity. We try to bring together experimental biology with calculative physics and mathematics to better understand information processing in the brain and the brain’s ability to change itself,” says Marianne.

Physics, mathematics and programming are therefore important parts of the researcher’s work when analysing what is happening in the rat’s brain.

If you think that research on rats’ brain cells sounds familiar, then you are probably right. Edvard and May-Britt Moser in Trondheim received the first Norwegian Nobel Prize in Medicine in 2014. The award was given to them for their discovery of a certain type of brain cells, so called grid cells. The grid cells alert the body to its location and how to find its way from point A to point B.

Marianne did her PhD with Edvard and May-Britt, playing an essential role in the work that led to the discovery of the grid cells. Marianne was therefore very involved in Norway securing its first Nobel Prize in Medicine.

 

The dark room

Another room in the animal section is completely dark. In the middle of the room, there is an enormous box with various equipment. In the centre of the box, there is a little mouse with an implant on its head.

In this test room, there is an advanced microscope. It uses a laser beam to read the brain activity of the mouse as it alternates between running and standing still on a treadmill.

The researcher Kristian Lensjø is back from a longer study break at the renowned Harvard University and will use some of the methods he has learned.

“I will train the mouse so that it understands that for example vertical lines on a screen mean reward and that horizontal lines give no reward. Then I will look at which brain cells are responsible for this type of learning,” says Kristian.

The students stand behind Kristian and watch the mouse and the computer screen. When the testing begins, they must close the microscope off with a curtain so that the mouse is alone in the dark box. Kristian assures us that the mouse is okay and that he can see what the mouse is doing through an infra-red camera.

“This room and the equipment is so new, we are still experiencing some issues with the tech,” says Marianne. But Christian fixes the problem and suddenly we see something on the computer screen that we have never seen before. It is a look into the mouse’s brain while it runs on the treadmill. This means that the researchers can watch the nerve cells as the mouse looks at vertical and horizontal lines, and detect where the brain activity occurs.

 

Research role models

The students from Ullern know they are lucky to see how cutting-edge neuroscience is done in real life. Marianne and her colleagues are far from nobodies in the research world. Bente Prestegård from Oslo Cancer Cluster and Monica Jenstad, the biology teacher at Ullern who coordinates the work placements, made sure to tell the students beforehand.

“This is a fantastic and unique opportunity for students to get a look into science on a high international level. They can see that the people behind the research are nice and just like any normal people. When seeing good role models, it is easier to picture a future in research for oneself,” says Monica.

“This is a fantastic and unique opportunity for students to get a look into science on a high international level.”

Monica and Marianne have known each other since they were master students together at the University of Tromsø almost twenty years ago.

“I know Marianne very well, both privately and professionally. She is passionate about her research and about dissemination and recruitment. She also works hard to create a positive environment for her research group. Therefore, it was natural to ask Marianne to receive the students and it wasn’t difficult to get her to agree,” says Monica.

Back in the first operating room, Dejana and Malin are still operating on the rats. They will spend the entire day doing this. It takes time when the equipment needs to be found and sterilised, the rats need to be sedated and then operated on as precisely as possibly. It is past noon and time for lunch for Marianne, Kristian and the Ullern students on work placement.

Before I leave them outside Niels Henrik Abels Hus at the Oslo University Campus, I take a picture to remember the extra-ordinary work placement. And not least: to store a picture of the memory in my own brain.

 

Finally, time for lunch! From the left: Emmy Hansteen, Benedicte Berggrav, researcher Marianne Fyhn, Lina Babusiaux, Maren Gjerstad Høgden and researcher Kristian Lensjø. Photo: Elisabeth Kirkeng Andersen.

Finally, time for lunch! From the left: Emmy Hansteen, Benedicte Berggrav, researcher Marianne Fyhn, Lina Babusiaux, Maren Gjerstad Høgden and researcher Kristian Lensjø. Photo: Elisabeth Kirkeng Andersen.

 

Sign up to OCC newsletter

Lab researcher from Nordic Nanovector

A successful first quarter for Nordic Nanovector

Nordic Nanovector raises NOK 225 million in private placements, begins phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company. These were some of the good news presented in the first quarter 2019 report.

Oslo Cancer Cluster’s member company Nordic Nanovector develops precision medicine against haematological cancers. These are the types of cancers affecting blood, bone marrow and lymph nodes – also known as leukaemia, lymphoma and myeloma. These cancers are notoriously difficult to treat and therefore have a highly unmet medical need.

On the morning of 23 May 2019, the CEO of Nordic Nanovector, Eduardo Bravo, presented some of the successes the company has had during the first quarter of 2019.

“As we advance the clinical development programmes with Betalutin, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner.”

The company’s highlights from the first quarter included raising approximately NOK 225 million in private placements.

They have also extended their clinical trials, known as the PARADIGME study, which address advanced, recurring follicular lymphoma. They now have phase II clinical trials in over 74 sites in 23 countries.

During the first quarter, Nordic Nanovector has also welcomed a new chairman to the Board of Directors – Jan H. Egberts, M.D. He is also the chairperson of the Board of Directors of Oslo Cancer Cluster member Photocure.

Lastly, Dr Mark Wright has been appointed Head of Manufacturing to lead the production of Nordic Nanovector’s therapies. This prepares Nordic Nanovector for future commercialisation and will hopefully lead to more precise treatments successfully reaching cancer patients.